%7B%22key%22:%22Poster%22%7D,%7B%22key%22:%22Abstract%22%7D%5D,%22meetingTypeName%22:%5B%7B%22key%22:%22ASCO%20Annual%20Meeting%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:%222024%22%7D%5D%7D&size=50
%7B%22key%22:%22Poster%22%7D,%7B%22key%22:%22Abstract%22%7D%5D,%22meetingTypeName%22:%5B%7B%22key%22:%22ASCO%20Annual%20Meeting%22%7D%5D,%22meetingYear%22:%5B%7B%22key%22:%222024%22%7D%5D%7D&size=50
RC-48不仅是首个License out的国产ADC新药，还刷新了中国创新药单药出海交易金额的新高。在本次ASCO大会上，荣昌生物将发布RC48有关的12项研究结果，形式包括8个Publication Only，3个Poster Session，以及1个Clinical Science Symposium。Poster Session之一为RC48辅助治疗或挽救HER2过表达的高风险非肌层浸润性膀胱癌的...
Poster Talks Explore How Policy, Payer Incentives Affect Cancer Care, Outcomes For all the therapeutic advances presented during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, there are simple realities: Patients cannot be treated if they have no access to care. Too many pat...
ASCO结直肠癌壁报讨论(PosterDiscussion)利用生物标志物和临床特征指导辅助治疗(LeveragingBiomarkersandClinicalCharacteristicstoGuideAdjuvantTherapy)#4009 ctDNA检测微小残留病灶,反映辅助治疗效果,并鉴别I-III期CRC患者的高复发风险#4010优化III期结肠癌决策制定的新型预后和预测工具#4011 IDEA协作组ACHIEVE-2试验中高危因素...